Small Cap Feast

Small Cap Feast – 23 September 2019

Dish of the Day:

No Joiners Today

Off the Menu:

No Leavers Today

What’s Cooking in the IPO Kitchen?


AMRYT PHARMA PLC— a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare or orphan diseases have raised $60m before expenses and will relist on the AIM Market on the 25/09/2019

Main Market Standard

VAALCO Energy, Inc. (NYSE: EGY), an independent energy company focused on development and production assets in West Africa, today announces its formal intention to seek a Standard Listing on the Main Market of London Stock Exchange (“LSE”), to complement its existing Listing on the New York Stock Exchange., the largest Payments, Marketplace and Fintech Ecosystem in Kazakhstan with a leading market share in each of its key products and services, announces today the expected publication of a registration document that has been submitted for approval to the FCA and its potential intention, subject to market conditions, to undertake an initial public offering .

Main Market premium

Registration document approved for Helios Towers. The Group provides essential network services, flexible infrastructure solutions and reliable power supply to mobile network operators  in five African growth economies.  Revenue increased 7 per cent. year-on-year to US$191m (H1 2018: US$178m), with Adjusted EBITDA up 15 per cent. year-on-year at US$99m (H1 2018: US$86m) for the six months ended 30 June 2019.

Breakfast Buffet

Nakama Group (NAK) 1.10p £1.30m

Last week, Nakama Group, the AIM quoted recruitment consultancy working across the UK and Asia providing recruitment and related services for the web, interactive, digital media, IT and business change sectors, announced its final results for the year ended 31 March 2019.


Group revenue decreased by 20.2per cent. to £13.4m (2018: £16.8m)

Net fee income reduced by 22.6 per cent. to £4.1m (2018: £5.3m)

Net fee income percentage decreased to 30.8 per cent. (2018: 31.6 per cent.)

Operating profit increased to £91,000 (2018: loss £1,480,000)

“Trading so far this year has been in line with expectations, however, exceptional costs will be incurred as we continue the restructuring of some local offices. Attracting strong talent and building a higher performance culture takes time and therefore we remain cautious on increasing operating profit margin. Our objective is to continue to focus on financial discipline and improving revenues and profit margins over the year ahead.”

Gfinity (GFIN) 4p £19.18m

Gfinity, a world-leading esports solutions provider, provides an update on a growing capability and revenue stream.

Gfinity specialises in the design, development and delivery of bespoke esports solutions for publishers, rights holders, brands and media organisations who are looking to connect or deepen relationships with young gamers. One of the solutions is community building and engagement.

Gfinity has built a rapidly growing and unique community of gamers via its online channels, organically connecting with more than 20 million gamers in the past four weeks. Through the provision of regular high-quality news, opinion pieces and creative content via RealSport101, a wholly owned Gfinity company, and and their respective social media channels, Gfinity is featured in the regular media consumption habits of millions of young gamers.

Since April, has seen a 42% increase in visitors, reaching 150,000 gamers every day with more than 2.5 million people regularly engaging via its Facebook page.  In addition, is continuing to attract a growing number of visitors, attracting 1 million viewers for the first time this month.

World High Life (LIFE) 11p £13.2m

World High Life Plc, a CBD and medicinal cannabis investment company, announced that it has agreed indicative terms for the Company’s first investment, the acquisition of Love Hemp Ltd . The Directors of World High Life believe that this initial investment will provide LIFE with a platform  from which it can work with Love Hemp to rapidly expand its UK and European business and help LIFE in its ambition to become a leading European medical cannabis and CBD investment company.


World High Life is proposing to acquire Love Hemp for a minimum consideration of £9 million

Love Hemp is a London-based supplier of a range of CBD and Hemp products

Love Hemp already has distribution agreements in place with UK supermarkets and health food stores

The Directors of World High Life believe that this investment and their expertise in the Cannabis sector will enable Love Hemp to accelerate its planned expansion

In the year ended 30 June 2018, Love Hemp made profit before tax of £532,097 on turnover of £2,501,857.

Crossword Cybersecurity* (CCS) 456p £23.64m

Crossword Cybersecurity, the cyber security technology commercialisation company, today announced HY Jun 19 results.


Orders received for Rizikon Assurance during the period were more than double those received in the same period last year

The Rizikon Assurance pipeline more than doubled in the first six months of this year and now stands in excess of £3 million over 100 companies in a wide range of sectors

Product and Consulting revenue increased by 21% over the same period in the prior year

Total revenue increased by 5% to £570,757

Total comprehensive loss for the period was £1,077,595, an increase of £246,804 over the same period in the prior year, following investment in product development and sales and marketing

Cash and Cash Equivalents at 30 June 2019 of £1,294,491.

Trading since the period end has continued to be encouraging, and the Directors are confident that full year results will be in line with market expectations.

PROACTIS Holdings (PHD) 51p £49m

Proactis, the global spend management company, announced that it has signed a long-term contract with DIWIDAG Systems International in Germany.

As announced at the time of the Interim Results during April 2019 the Group took a strategic decision to focus more tightly on a specific market segment with a focussed product portfolio with a view to improving its new business performance in the US, France and Germany.

This contract win represents a strategically important milestone, being the first new customer in Germany to sign up under that new strategy. This demonstrates the capability of its marketing and sales team to align its efforts to the needs of customers within that specific market segment and the suitability of the focussed product portfolio for that market segment.

Intelligent Ultrasound (MED) 10.5p £22.55m

Intelligent Ultrasound, the intelligent ultrasound software and simulation company, announces that its database used in the development of its artificial intelligence (“AI”) products now exceeds four million ultrasound images.

The continued growth of the Group’s image database is an important component of the Company’s strategy, as the image library will help it develop additional AI-based software solutions that can automatically recognise and assess ultrasound images to improve the speed and quality of medical ultrasound scanning across a number of clinical applications.

In July 2019, the Group announced that it had signed its first long term licence and co-development agreement for its AI software with one of the world’s leading ultrasound equipment manufacturers. The long-term agreement will enable the integration of Intelligent Ultrasound’s real-time image analysis software onto a range of specialty specific ultrasound systems within the global healthcare market.

Osirium Technologies (OSI) 48p £6.17m

Osirium Technologies, a leading vendor of cloud-based cybersecurity software, announced a significant contract win with a major UK provider of software and IT services to the public sector. The contract represents a substantial expansion by this customer of its investment in Osirium, following an initial order, as announced on 12 February.

Under the terms of the contract, Osirium will deliver its full PxM Platform including the Privileged Access Management, Privileged Task Management and Privileged Session Management modules. The 36 month license is for 2,600 devices, in addition to the 250 devices covered by the initial order. Osirium’s software will enable this service provider to deliver managed security services to its customers, principally central government organisations and local authoriities in the public sector, delivering rigorous control of access to privileged accounts.

4D PHARMA (DDDD) 82p £53.54m

4D pharma, a pharmaceutical company leading the development of Live Biotherapeutics, announced the publication of a paper outlining the ability of MRx0005 and MRx0029 to modulate neuroinflammatory and neurodegenerative processes in vitro.

The paper ‘In vitro characterisation of gut microbiota-derived bacterial strains with neuroprotective properties’ is published in the journal Frontiers in Cellular Neuroscience.

Through screening a panel of gut bacterial strains using the Company’s MicroRx® platform, 4D researchers have identified two single-strain Live Biotherapeutic candidates, MRx0005 and MRx0029 with potent effects on neuroinflammation and intrinsic antioxidant capacity. MRx0029 also displayed neuroprotective properties and induced a mature phenotype in undifferentiated neuronal cells. The team were able to associate many of the observed effects with specific short-chain fatty acids produced

MTI Wireless Edge (MWE) 31p £26.23m

MTI Wireless Edge Ltd, the technology group, focused on comprehensive communication and radio frequency solutions across multiple sectors, announced that its antenna division has received an order valued at approximately US$1 million, for the supply of military antennas to a European customer over the next 15 months.

Thruvision Group (THRU) 27.60p £39.13m

Thruvision the specialist provider of people-screening technology to the international security market, announced a strategically important contract award by the US Government’s Customs and Border Protection (CBP) totalling $3.0 million, of which $2.9 million will be delivered in FY20.

Head Chef:

Derren Nathan
0203 764 2344

*A corporate client of Hybridan LLP


This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email with “unsubscribe me”.